SCHEMBL5658723

SCHEMBL5658723

Cc1ccc2c(c1)C(=O)C(=O)N2Cc1ccccc1C#N

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.62
MAPT P10636 7/20 0.57
TP53 P04637 2/20 0.57
ALDH1A1 P00352 6/20 0.50
LMNA P02545 4/20 0.50
HSP90AA1 P07900 1/20 0.50
TGM2 P21980 1/20 0.50
KMT2A Q03164 4/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CHRM5 P08912 2/20 0.48
POLB P06746 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 3/20 0.46
RCE1 Q9Y256 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18974296 0.84 TGM2 (0.57) ACHEMAPTTP53ALDH1A1TGM2
SCHEMBL5659376 0.83 ACHE (0.69) ACHEMAPTTP53ALDH1A1LMNA
SCHEMBL18954770 0.82 CA1 (0.69) CA12CA1CA2CA9
SCHEMBL28070700 0.81 ACHE (0.66) ACHEMAPTTP53ALDH1A1LMNA
SCHEMBL28075277 0.81 CA12 (0.67) ACHEMAPTTP53ALDH1A1LMNA
SCHEMBL5659656 0.81 ACHE (0.66) ACHEMAPTTP53ALDH1A1LMNA
SCHEMBL28220867 0.80 ACHE (0.63) ACHEMAPTTP53ALDH1A1LMNA
SCHEMBL18954858 0.79 ACHE (0.63) ACHEMAPTTP53ALDH1A1LMNA
SCHEMBL578250 0.77 ACHE (0.74) ACHEMAPTTP53ALDH1A1LMNA
SCHEMBL2495943 0.74 MAPT (0.71) ACHEMAPTTP53ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed
EP-1487792-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-12-22 EP disclosed
WO-2003078394-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 ACHE 4757/4885MAPT 3588/4885TP53 3370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.